Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed » Globe Newswire - TCN.VN

Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis 26-02-2024, 14:05

FloQast Launches “How to Prevent an MLB Lockout”: An 8-Part Series Exposing the Financial Reality Behind Major League Baseball’s Looming Labor Woes 3-02-2026, 21:00

LeddarTech Showcasing Its Award-Winning Sensor Fusion and Perception Software and High-Performance Products That Enable ADAS and AD at Tech.AD Berlin on March 26-28, 2023 8-03-2023, 12:07

21-09-2025, 09:15

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

Notified -

Globe Newswire21-09-2025, 09:15

21-09-2025, 09:15

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

Notified -

Globe Newswire21-09-2025, 09:15

21-09-2025, 09:15

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

Notified -

Globe Newswire21-09-2025, 09:15

Liên hệ quảng cáo

Hotline hỗ trợ quảng cáo: 0914.222.131
Email: quangcao@vietsoftgroup.com

Email: info@vietsoftgroup.com

© Copyright 2019 - Trang tin tức chuyên đề giới trẻ TCN News - Toàn bộ bài viết được chi sẻ bởi các thành viên.